|Systematic (IUPAC) name|
|Trade names||Robitussin, Delsym, DM, DexAlone, Duract|
|Metabolism||Hepatic (liver) enzymes: major CYP2D6, minor CYP3A4, and minor CYP3A5|
|Half-life||2-4 hours (extensive metabolisers); 24 hours (poor metabolisers)|
|Mol. mass||271.40 g/mol|
|Melt. point||111 °C (232 °F)|
Dextromethorphan (DXM or DM) is an antitussive (cough suppressant) drug. It is one of the active ingredients in many over-the-counter cold and cough medicines, including generic labels and store brands, Benylin DM, Mucinex DM, Robitussin, NyQuil, Dimetapp, Vicks, Coricidin, Delsym, TheraFlu, and others. Dextromethorphan has also found other uses in medicine, ranging from pain relief to psychological applications. It is sold in syrup, tablet, spray, and lozenge forms. In its pure form, dextromethorphan occurs as a white powder.
DXM is also used recreationally. When exceeding label-specified maximum dosages, dextromethorphan acts as a dissociative hallucinogen. Its mechanism of action is via multiple effects, including actions as a nonselective serotonin reuptake inhibitor and a sigma-1 receptor agonist. DXM and its major metabolite, dextrorphan, also acts as an NMDA receptor antagonist at high doses, which produces effects similar to, yet distinct from, the dissociative states created by other dissociative anaesthetics such as ketamine and phencyclidine. As well, the metabolite 3-methoxymorphinan of dextrorphan (thus a second-level metabolite of DXM) produces local anesthetic effects in rats with potency above dextrorphan, but below that of DXM.
The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants.
A 2011 Cochrane systematic review of randomized controlled trials comparing dextromethorphan, diphenhydramine, and honey for treating cough symptoms in children found that dextromethorphan and honey were similarly effective at reducing cough frequency.
A combination of dextromethorphan and quinidine, a CYP2D6 inhibitor, has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. Dextromethorphan is also being investigated as a possible treatment for neuropathic pain and pain associated with fibromyalgia. In 2010, the FDA approved the combination product dextromethorphan/quinidine (Nuedexta) for the treatment of pseudobulbar affect (PBA).
Over-the-counter preparations containing dextromethorphan have been used in manners inconsistent with their labeling, often as a recreational drug. At doses much higher than medically recommended, DXM and its major metabolite, dextrorphan, acts as an NMDA receptor antagonist, which produces effects similar to, yet distinct from, the dissociative hallucinogenic states created by other dissociative anaesthetics such as ketamine and phencyclidine. It may produce distortions of the visual field - feelings of dissociation, distorted bodily perception, and excitement, as well as a loss of sense of time. Some users report stimulant-like euphoria, particularly in response to music. Dextromethorphan usually provides its recreational effects in a non-linear fashion, so that they are experienced in significantly varied stages. These stages are commonly referred to as "plateaus".
At normal doses:
- body rash/itching (see below)
- Closed-eye hallucination
At doses three to 10 times the recommended therapeutic dose:
- Increased energy
- Increased confidence
- Mild nausea
- "Speeding"/talking fast
- Feelings of increased strength
- Enlargened pupils/glazed eyes (but not red)
At dosages 15 to 75 times the recommended therapeutic dose:
- Blurred vision and/or double vision
- Bloodshot eyes
- Dilated pupils
- Shallow respiration
- Urinary retention
- Muscle spasms
- Sight loss
- Inability to focus eyes
- Skin rash
Because dextromethorphan can trigger a histamine release (allergic reaction), atopic children, who are especially susceptible to allergic reactions, should be administered dextromethorphan only if absolutely necessary, and only under the strict supervision of a healthcare professional.
Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome, which is a potentially life-threatening condition that can occur rapidly, due to a buildup of an excessive amount of serotonin in the body. Dextromethorphan can also cause serotonin syndrome when used with SSRI medicines, an interaction which has been documented in clinical cases where dextromethorphan is taken at recreational doses. The link between therapeutic dosages of dextromethorphan and serotonin syndrome has been suggested to be less conclusive.
Caution should be exercised when taking dextromethorphan when drinking ) generally are recommended to be avoided while using dextromethorphan and numerous other medications.
Testing for this drug is done either by blood or by urine. Blood can be either serum or plasma. Urine requires only 2 ml minimum.
Dextromethorphan is the dextrorotatory enantiomer of levomethorphan, which is the methyl ether of levorphanol, both opioid analgesics. It is named according to IUPAC rules as (+)-3-methoxy-17-methyl-9α,13α,14α-morphinan. As the pure free base, dextromethorphan occurs as an odorless, white to slightly yellow crystalline powder. It is freely soluble in chloroform and insoluble in water. Dextromethorphan is commonly available as the monohydrated hydrobromide salt, however some newer extended-release formulations contain dextromethorphan bound to an ion exchange resin based on polystyrene sulfonic acid. Dextromethorphan's specific rotation in water is +27.6° (20 °C, Sodium D-line).
Dextromethorphan has been shown to possess the following properties, mainly in binding assays to various receptors of animal tissues. Low Ki values mean strong binding or high affinity; high Ki values mean weak binding to the target or low affinity:
- Uncompetitive NMDA receptor (PCP site) antagonist (Ki = 7,253 nM).
- σ1 and σ2 sigma receptor agonist (Ki = 205 nM and 11,060 nM, respectively).
- α3β4-, α4β2-, and α7-nACh receptor (Ki = in the μM range) antagonist. Dextromethorphan binds to nicotinic receptors in frog eggs (Xenopus oocytes), human embryonic kidney cells and mouse tissue. It inhibits the antinociceptive (pain killing) action of nicotine in the tail-flick test in mice, where mouse tails are exposed to heat, which makes the mouse flick its tail if it feels pain.
- μ-, δ-, and κ-opioid receptor agonist (Ki = 1,280 nM, 11,500 nM, and 7,000 nM, respectively)
- SERT and NET inhibitor (Ki = 23 nM and 240 nM, respectively)
- NADPH oxidase inhibitor.
Its affinities for some of the sites listed are relatively very low and are probably insignificant, such as binding to NMDA receptors and opioid receptors, even at high recreational doses. Instead of acting as a direct antagonist of the NMDA receptor itself, dextromethorphan likely functions as a prodrug to its nearly 10-fold more potent metabolite dextrorphan, and this is the true mediator of its dissociative effects. What role, if any, (+)-3-methoxymorphinan, dextromethorphan's other major metabolite, plays in its effects is not entirely clear.
At therapeutic doses, dextromethorphan acts centrally (meaning that it acts on the brain) as opposed to locally (on the respiratory tract). It elevates the threshold for coughing, without inhibiting ciliary activity. Dextromethorphan is rapidly absorbed from the gastrointestinal tract and converted into the active metabolite dextrorphan in the liver by the cytochrome P450 enzyme CYP2D6. The average dose necessary for effective antitussive therapy is between 10 and 45 mg, depending on the individual. The International Society for the Study of Cough recommends "an adequate first dose of medication is 60 mg in the adult and repeat dosing should be infrequent rather than the qds recommended."
The duration of action after oral administration is about three to eight hours for dextromethorphan-hydrobromide, and 10 to 12 hours for dextromethorphan-polistirex. Around one in 10 of the Caucasian population has little or no CYP2D6 enzyme activity, leading to long-lived high drug levels.
The first pass through the hepatic portal vein results in some of the drug's being metabolized by O-demethylation into an active metabolite of dextromethorphan called dextrorphan (DXO). DXO is the 3-hydroxy derivative of dextromethorphan. The therapeutic activity of dextromethorphan is believed to be caused by both the drug and this metabolite. Dextromethorphan also undergoes N-demethylation (to 3-methoxymorphinan or MEM), and partial conjugation with glucuronic acid and sulfate ions. Hours after dextromethorphan therapy, (in humans) the metabolites (+)-3-hydroxy-N-methylmorphinan, (+)-3-morphinan, and traces of the unchanged drug are detectable in the urine.
A major metabolic catalyst involved is the cytochrome P450 enzyme known as 2D6, or CYP2D6. A significant portion of the population has a functional deficiency in this enzyme and are known as poor CYP2D6 metabolizers. O-demethylation of DXM to DXO contributes to at least 80% of the DXO formed during DXM metabolism. As CYP2D6 is a major metabolic pathway in the inactivation of dextromethorphan, the duration of action and effects of dextromethorphan can be increased by as much as three times in such poor metabolizers. In one study on 252 Americans, 84.3% were found to be "fast" (extensive) metabolizers, 6.8% to be "intermediate" metabolizers, and 8.8% were "slow" metabolizers of DXM. A number of alleles for CYP2D6 are known, including several completely inactive variants. The distribution of alleles is uneven amongst ethnic groups.
A large number of medications are potent inhibitors of CYP2D6. Some types of medications known to inhibit CYP2D6 include certain SSRIs and tricyclic antidepressants, some antipsychotics, and the commonly available antihistamine diphenhydramine. Therefore, the potential of interactions exists between dextromethorphan and medications that inhibit this enzyme, particularly in slow metabolizers. DXM is also metabolized by CYP3A4. N-demethylation is primarily accomplished by CYP3A4, contributing to at least 90% of the MEM formed as a primary metabolite of DXM.
A number of other CYP enzymes are implicated as minor pathways of DXM metabolism. CYP2B6 is actually more effective than CYP3A4 at N-demethylation of DXM, but, since the average individual has a much lower CYP2B6 content in his/her liver relative to CYP3A4, most N-demethylation of DXM is catalyzed by CYP3A4.
The racemic parent compound racemorphan was first described in a Swiss and US patent application from Hoffmann-La Roche in 1946 and 1947, respectively; a patent was granted in 1950. A resolution of the two isomers of racemorphan with tartaric acid was published in 1952, and DXM was successfully tested in 1954 as part of US Navy and CIA-funded research on nonaddictive substitutes for codeine. DXM was approved by the FDA in 1958 as an over-the-counter antitussive. As had been initially hoped, DXM was a solution for some of the problems associated with the use of codeine phosphate as a cough suppressant, such as sedation and opiate dependence, but like the dissociative anesthetics phencyclidine and ketamine, DXM later became associated with nonmedical use.
During the 1960s and 1970s, dextromethorphan became available in an over-the-counter tablet form by the brand name Romilar. In 1973, Romilar was taken off the shelves after a burst in sales because of frequent misuse, and was replaced by cough syrup in an attempt to cut down on abuse. The advent of widespread internet access in the 1990s allowed users to rapidly disseminate information about DXM, and online discussion groups formed around use and acquisition of the drug. As early as 1996, DXM HBr powder could be purchased in bulk from online retailers, allowing users to avoid consuming DXM in syrup preparations. As of January 1, 2012, dextromethorphan is prohibited for sale to minors in the state of California, except with a doctor's prescription.
- Cough syrup
- (+)-Naloxone - another dextrorotatory enantiomer of an opioid drug with useful nonopioid effects
- Kukanich B, Papich MG (2004). "Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs". J. Vet. Pharmacol. Ther. 27 (5): 337–41.
- "Balminil DM, Benylin DM (dextromethorphan) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 15 April 2014.
- "Reference Tables: Description and Solubility - D". Retrieved 2011-05-06.
- Schwartz AR, Pizon AF, Brooks DE (September 2008). "Dextromethorphan-induced serotonin syndrome". Clinical Toxicology (Philadelphia, Pa.) 46 (8): 771–3.
- Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP, Baek IH, Kim WK, Maurice T, Nabeshima T, Kim HC (May 2007). "Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats". Neurochemistry International 50 (6): 791–9.
- Shin EJ, Nah SY, Kim WK, Ko KH, Jhoo WK, Lim YK, Cha JY, Chen CF, Kim HC (April 2005). "The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan".
- Hou CH, Tzeng JI, Chen YW, Lin CN, Lin MT, Tu CH, Wang JJ (2006). "Dextromethorphan, 3-methoxymorphinan, and dextrorphan have local anesthetic effect on sciatic nerve blockade in rats". European Journal of Pharmacology 544 (1-3): 10–6.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust.
- Oduwole, O; Meremikwu, MM; Oyo-Ita, A; Udoh, EE (Mar 14, 2012). "Honey for acute cough in children.". The Cochrane database of systematic reviews 3: CD007094.
- Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA (2004). "Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial". Neurology 63 (8): 1364–70.
- "Cough Drug May Help Fibromyalgia Pain". WebMD.
- Koyuncuoğlu H, Güngör M, Sağduyu H, Aricioğlu F (Apr 1990). "Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats". Pharmacol Biochem Behav. 35 (4): 829–32.
- "Dextromethorphan (DXM)". Cesar.umd.edu. Retrieved 2013-07-28.
- "Dextromethorphan". Drugs and Chemicals of Concern.
- Giannini AJ (1997). Drugs of abuse (2nd ed.). Los Angeles, Calif.: Practice Management Information Corp.
- "Dextromethorphan". NHTSA.
- "Teen Drug Abuse: Cough Medicine and DXM (Dextromethorphan)". webmd.
- Olney JW, Labruyere J, Price MT (1989). "Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs". Science 244 (4910): 1360–2.
- Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL (2007). "Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain". NeuroToxicology 28 (4): 813–8.
- WHO Expert Committee on Drug Dependence (1970). "Seventeenth Report" (PDF). World Health Organization. Retrieved 2008-12-29.
- "Inhibitors of CYP3A4". ganfyd.org. Retrieved 23 August 2013.
- Burns JM, Boyer EW. Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. doi: 10.2147/SAR.S36761. eCollection 2013. PMID 24648790 PMCID PMC3931656
- Damaj MI, Flood P, Ho KK, May EL, Martin BR (2004). "Effect of Dextrometorphan and Dextrorphan on Nicotine and Neuronal Nicotinic Receptors: In Vitro and in Vivo Selectivity". Journal of Pharmacology and Experimental Therapeutics 312 (2): 780–5.
- Lee JH, Shin EJ, Jeong SM, Kim JH, Lee BH, Yoon IS, Lee JH, Choi SH, Lee SM, Lee PH, Kim HC, Nah SY (2006). "Effects of dextrorotatory morphinans on α3β4 nicotinic acetylcholine receptors expressed in Xenopus oocytes". European Journal of Pharmacology 536 (1-2): 85–92.
- Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ (2000). "Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors". The Journal of Pharmacology and Experimental Therapeutics 293 (3): 962–7.
- Codd EE, Shank RP, Schupsky JJ, Raffa RB (1995). "Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception". The Journal of Pharmacology and Experimental Therapeutics 274 (3): 1263–70.
- Schwartz AR, Pizon AF, Brooks DE (2008). "Dextromethorphan-induced serotonin syndrome". Clinical toxicology (Philadelphia, Pa.) 46 (8): 771–3.
- Henderson MG, Fuller RW (1992). "Dextromethorphan antagonizes the acute depletion of brain serotonin by p-chloroamphetamine and H75/12 in rats". Brain Research 594 (2): 323–6.
- Gillman PK (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia 95 (4): 434–41.
- Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Zhang W, Hong JS, Liu B (2004). "Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase". FASEB J. 18 (3): 589–91.
- Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research 821 (2): 516–9.
- Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI (1997). "Metabolism of Dextromethorphan in vitro: Involvement of Cytochromes P450 2D6 and 3A3/4, with a Possible Role of 2E1". Biopharmaceutics & Drug Disposition 18 (3): 227–240.
- Professor Alyn H Morice paper titled 'Cough' par. 'Dextromethorphan' http://www.issc.info/cough.html
- Morice AH. "Cough". International Society for the Study of Cough.
- Yu A, Haining RL (2001). "Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?". Drug metabolism and disposition: the biological fate of chemicals 29 (11): 1514–20.
- Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA (1996). "The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans". Clin. Pharmacol. Ther. 60 (3): 295–307.
- Woodworth JR, Dennis SR, Moore L, Rotenberg KS (1987). "The polymorphic metabolism of dextromethorphan". Journal of clinical pharmacology 27 (2): 139–43.
- Morris, H.; Wallach, J. (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis 6 (7-8): 614–32.
- "Memorandum for the Secretary of Defense" (PDF). Retrieved 2013-07-28.
- "Senate Bill No. 514". An act to add Sections 11110 and 11111 to the Health and Safety Code, relating to nonprescription drugs. State of California, Legislative Counsel.
- U.S. National Library of Medicine: Drug Information Portal - Dextromethorphan
- Nuedexta (dextromethorphan hydrobromide and quinidine sulfate): Prescribing Information (Original Approval Date FDA: October 29, 2010)